Potential Association of a Common L-FABP Polymorphism With Lipid-induced Hepatic Insulin Resistance
NCT ID: NCT00277342
Last Updated: 2012-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2006-01-31
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
NCT01997424
Role of Regulatory B Cells in the Pathogenesis of Metabolic Associated Fatty Liver Disease
NCT04720560
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression
NCT02267148
Prevalence of NAFLD in T1DM Patients
NCT06445361
Prospective Cohort Study in Patients With NAFLD
NCT00575133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
measurement of lipid-induced hepatic insulin resistance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnant or lactating women, menstrual irregularities
* cortisone, antidiabetic drugs
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Institute of Human Nutrition
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin O Weickert, MD
Role: PRINCIPAL_INVESTIGATOR
German Institute of Human Nutrition; Charité Campus Benjamin Franklin
Matthias Möhlig, MD
Role: PRINCIPAL_INVESTIGATOR
German Institute of Human Nutrition; Charité Campus Benjamin Franklin
Andreas FH Pfeiffer, MD
Role: STUDY_CHAIR
German Institute of Human Nutrition; Charité Campus Benjamin Franklin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
German Institute of Human Nutrition DIfE, Dpt. of Clinical Nutrition, Potsdam-Rehbrücke
Nuthetal, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weickert MO, Loeffelholz CV, Roden M, Chandramouli V, Brehm A, Nowotny P, Osterhoff MA, Isken F, Spranger J, Landau BR, Pfeiffer AF, Mohlig M. A Thr94Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects. Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E1078-84. doi: 10.1152/ajpendo.00337.2007. Epub 2007 Aug 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOW_MM_LFABP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.